Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta TherapeuticsSRPT -3.51%53 Debt-to-Equity is 0.69 as of Jun. 2026, which is 23% below its 10-year median of 0.90. GuruFocus rates SRPT with a GF Score™ of 53/100 and a GF Value™ of $109.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Sarepta Therapeutics ranks worse than 81.66% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sarepta Therapeutics's Debt-to-Equity or its related term are showing as below:
SRPT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.9 Max: 4.2
Current: 0.69
During the past 13 years, the highest Debt-to-Equity Ratio of Sarepta Therapeutics was 4.20. The lowest was 0.03. And the median was 0.90.
SRPT's Debt-to-Equity is ranked worse than 81.66% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs SRPT: 0.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sarepta Therapeutics Debt-to-Equity Related Terms
Sarepta Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRPT vs MPLT, ZYME, ABCL: Debt-to-Equity Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (SRPT) has a Debt-to-Equity of 0.69 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sarepta Therapeutics and its competitors. This is 23% below median its historical median of 0.90. Over the past decade, Sarepta Therapeutics' Debt-to-Equity has ranged from 0.03 to 4.20. According to the industry distribution chart, Sarepta Therapeutics ranks #779 out of 954 companies in the Biotechnology industry, placing it in the top 81.7%.
Is Sarepta Therapeutics' Debt-to-Equity too high?
Sarepta Therapeutics' current Debt-to-Equity of 0.69 is 23% below median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 4.20. The Biotechnology industry median Debt-to-Equity is 0.16. Sarepta Therapeutics' value of 0.69 is 331.3% above this industry median. Based on the distribution chart, Sarepta Therapeutics ranks #779 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Debt-to-Equity compare to MPLT and ZYME?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #779 out of 954 companies for Debt-to-Equity. This places Sarepta Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Sarepta Therapeutics' value of 0.69 is 331.3% above this benchmark. Historically, Sarepta Therapeutics' own Debt-to-Equity has ranged from 0.03 to 4.20 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.16, Sarepta Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sarepta Therapeutics's current Debt-to-Equity of 0.69 is 331.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Debt-to-Equity is 0.69, which is 23% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is $109.19, compared to a current price of $18.13 — trading 83.4% below its estimated fair value. The current Debt-to-Equity is 0.69, which is 23% below median its 10-year median of 0.90 and 331.3% above the Biotechnology industry median of 0.16. Sarepta Therapeutics' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sarepta Therapeutics (SRPT), the current Debt-to-Equity is 0.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $18.13 is trading 83.4% below its estimated GF Value™ of $109.19.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for SRPT:
Debt-to-Equity: 0.69 (23% below median its 10-year median of 0.90)
GF Value™: $109.19 vs. price of $18.13 (83.4% below fair value)
Industry Position: 331.3% above the Biotechnology median (#779 of 954)
No single metric tells the full story. See the SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
53GF Score
Get the complete analysis for SRPT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRPT has been successfully added to your 
